[Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
This review addresses molecular targeted therapies for metastatic breast cancer. As the complex cellular aberrations inherent to cancer cells continue to be revealed, new therapies to target specific cellular pathways are being developed, and several are currently in clinical trials. The most promising of these new agents are discussed focusing on monoclonal antibodies and tyrosine kinase inhibitors to human epidermal growth factor receptors (HER) and vascular endothelial growth factor (VEGF).
Nielsen
Dorte Lisbet
DL
Herlev Hospital, Onkologisk Afdeling, Herlev. doni@heh.regionh.dk
Andersson
Michael
M
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D066246:ErbB Receptors / Q000187:drug effects / Q000378:metabolism; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D006801:Humans; D000077341:Lapatinib; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000187:drug effects / Q000378:metabolism; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077341:Lapatinib; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D040262:Receptors, Vascular Endothelial Growth Factor; C485206:pertuzumab; D000068878:Trastuzumab; D000077156:Gefitinib